Kindstar Globalgene Technology’s US$285.2 Million IPO

S&C acted as Hong Kong and U.S. counsel to the joint sponsors and underwriters, including Goldman Sachs, CICC and Credit Suisse.

Kindstar Globalgene Technology, Inc. completed its global offering and listing on The Stock Exchange of Hong Kong Limited, raising gross proceeds of approximately US$285.2 million (which could rise to US$328 million if the over-allotment option is exercised in full).

Kindstar Globalgene is a leading clinical testing service provider, with the largest esoteric testing portfolio among all independent esoteric testing providers in China.

The S&C team was led by Ching-Yang Lin (Picture) and Kay Ian Ng in Hong Kong and Gwen Wong in Beijing and included Stephen Pang, Johnny Han and Guanlin Wang.

Involved fees earner: Johnny Han – Sullivan & Cromwell; Ching-Yang Lin – Sullivan & Cromwell; Kay Ian Ng – Sullivan & Cromwell; Stephen Pang – Sullivan & Cromwell; Guanlin Wang – Sullivan & Cromwell; Gwen Wong – Sullivan & Cromwell;

Law Firms: Sullivan & Cromwell;

Clients: China International Capital Corporation Limited (CICC); Credit Suisse; Goldman Sachs & Co.;

Author: Sonia Carcano